Updated Jul 16, 2026
Bizily Scott has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $337K.
Scott Bizily is the Chief Legal Officer at 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company. He has been involved in various SEC filings related to the company, indicating his active role in corporate governance and legal matters.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 6.6K | $14.00 | $92K |
| 2026-07-02 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise | 5.8K | $6.49 | $37K |
| 2026-07-02 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise | 814 | $4.14 | $3K |
| 2026-06-25 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 9.8K | $12.00 | $118K |
| 2026-06-25 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise | 9.8K | $4.14 | $41K |
| 2025-12-19 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.6K | $10.90 | $18K |
| 2025-12-19 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise [10b5-1] | 1.6K | $4.14 | $7K |
| 2025-11-20 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.6K | $10.59 | $17K |
| 2025-11-20 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise [10b5-1] | 1.6K | $4.14 | $7K |
| 2025-10-27 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 2.7K | $12.00 | $32K |
| 2025-10-27 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise | 1.1K | $6.49 | $7K |
| 2025-10-20 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 1.6K | $10.17 | $17K |
| 2025-10-20 | FDMT | 4D Molecular Therapeutics, Inc. | M — Option exercise | 1.6K | $4.14 | $7K |
| 2025-10-09 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 2.4K | $10.00 | $24K |
| 2025-09-23 | FDMT | 4D Molecular Therapeutics, Inc. | S — Open-market sale | 2.4K | $8.00 | $19K |
Scott Bizily is the Chief Legal Officer at 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company. He has been involved in various SEC filings related to the company, indicating his active role in corporate governance and legal matters.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 8 open-market sales ($337K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Bizily Scott profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.